ANALYZES OF ANTIPLATELETS AND ANTICOAGULANTS UTILIZATION IN PATIENTS TREATED IN CARDIOVASCULAR REHABILITATION CENTER FROM CROATIA

Marko Boban, Viktor Persic, Vladimir Pesa, Vesna Pehar-Pejcinovic, Dzemail Detanac, Tomislav Sipic, Marinko Zulj, Tamara Franovic, Aleksandar Vcev

Abstract


Purpose: Discordance with the guidelines and underutilization of pharmacotherapy for secondary prevention frequently exists in clinical practice. Aim of our study was to assess the prescription routine and drug utilization patterns for antiplatelets and peroral anticoagulants in tertiary medical center specialized for cardiovascular rehabilitation.

Methods: study included 96 consecutive patients scheduled for cardiovascular rehabilitation in period 1-6 months after the acute treatment for ischemic 87(80.2%) and valvular heart disease 18(19.8%).  Patients were divided according to etiology of heart disease and type of acute cardiovascular treatments (conservative, percutaneous coronary interventions (PCI) and surgery).

Results: Dual antiplatelet therapy was the most commonly applied regimen in 84(87.5%) of conservatively treated myocardial infarctions, 47(61.9%) of percutaneous coronary interventions (PCI) and 13(58.9%) of surgically treated group (p>0.05). Among studied group of patients significant differences in utilization were found for warfarin, or combinations of antiplatelets with warfarin(p<0.001), as well as studied etiologies of heart disease(p<0.001), whilst there were no differences for those groups for studied antiplatelets drugs(p>0.05). All four of patients that received triple therapy (4.17%) were from surgical group. Underutilization of antiplatelets in ischemic heart disease was at 11(14.3%) what was congruent with the developed industrial nations.

 Conclusions:  Acute cardiovascular treatment type, but not heart disease etiology, had significant influence on subsequent prescription routine. Decreased use of pharmacological agents for secondary prevention in surgical patients was revealed. Drug utilization analyzes can offer improvement in optimizing medical treatments, quality of care and decrease unnecessary polypragmasia, as well as improve economical efficiency of medical management.


Keywords


drug utilization (DU) review; antiplatelets (AP); anticoagulants; warfarin; cardiovascular rehabilitation; ischemic heart disease; valvular heart disease

Full Text:

PDF

References


Meade T. Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. Handb Exp Pharmacol. 2012;(210):565-605.

Toscani MR, Makkar R, Bottorff MB. Quality improvement in the continuum of care: Impact of atherothrombosis in managed care pharmacy. J Manag Care Pharm. 2004;10(6 Suppl A):S2-12; quiz S13-16.

Ho WK, Hankey GJ, Eikelboom JW. Prevention of coronary heart disease with aspirin and clopidogrel: Efficacy, safety, costs and cost-effectiveness. Expert Opin Pharmacother. 2004;5(3):493-503.

Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001;103(3):363-8.

Sambola A, Ferreira-Gonzalez I, Angel J, et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: The musica study. Heart. 2009;95(18):1483-8.

Kotseva K, Wood D, De Backer G, et al.Euroaspire III. A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 european countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-37.

Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the american society of echocardiography and the european association of cardiovascular imaging. European heart journal cardiovascular Imaging. 2015;16(3):233-71.

Griffo R, Ambrosetti M, Tramarin R, Fattirolli F, Temporelli PL, Vestri AR, et al. Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the icaros survey. Int J Cardiol. 2013;167(4):1390-5.

Patrono C, Baigent C. Low-dose aspirin, coxibs, and other nsaids: A clinical mosaic emerges. Mol Interv. 2009;9(1):31-9.

Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: Effect on inducible nitric oxide synthase. Proc Natl Acad Sci USA. 1995;92(17):7926-30.

Kopp E, Ghosh S. Inhibition of nf-kappa b by sodium salicylate and aspirin. Science. 1994;265(5174):956-9.

Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60.

Hennekens CH, Knatterud GL, Pfeffer MA. Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: Clinical and research challenges. Diabetes Care. 2004;27(11):2752-4.

Tufano A, Cimino E, Di Minno MN, et al. Diabetes mellitus and cardiovascular prevention: The role and the limitations of currently available antiplatelet drugs. Int J Vasc Med. 2011;2011:250518

Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc). J Hypertens. 2007;25(6):1105-87.

Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347(17):1309-17.

Kushner FG, Hand M, Smith SC, Jr., et al. 2009 focused updates: Acc/aha guidelines for the management of patients with st-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and acc/aha/scai guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2009;54(23):2205-41.

Hennekens CH, Schneider WR. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Rev Cardiovasc Ther. 2008;6(1):95-107.

Hennekens CH, Jonas MA, Buring JE. The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the united states. Arch Intern Med. 1994;154(1):37-9.

Tantry US, Gesheff M, Liu F, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: what progress has been made? Expert Opin Pharmacother. 2014;15(17):2553-64.

Petricevic M, Milicic D, White A, et al. Development of a concept for a personalized approach in the perioperative antiplatelet therapy administration/discontinuation management based on multiple electrode aggregometry in patients undergoing coronary artery surgery. J Thromb Thrombolysis. 2015;40(3):383-91.

Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther. 2014;141(1):69-78.

Petricevic M, Biocina B, Boban M, et al. Clinical Relevance and Practical Value of Platelet Function Assessment Using Multiple Electrode Aggregometry during Extracorporeal Circulation.Thorac Cardiovasc Surg. 2015; 63(4):351-2.

Floyd CN, Ferro A. Antiplatelet drug resistance: Molecular insights and clinical implications. Prostaglandins Other Lipid Mediat. 2015;120:21-7.

Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17.

Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet adp receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107(12):1591-8.

Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129(5):394-405.

Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol. 2006;47(5):939-43.

Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation. 2012;125(16):2015-26.

Hylek EM, Solarz DE. Dual antiplatelet and oral anticoagulant therapy: Increasing use and precautions for a hazardous combination. JACC Cardiovasc Interv. 2008;1(1):62-4.

Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27(5):519-26.

Schurgers LJ, Dissel PE, Spronk HM, et al. Role of vitamin k and vitamin k-dependent proteins in vascular calcification. Z Kardiol. 2001;90 (Suppl 3):57-63.

Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143(4):241-50.

Reiner Z, Mihatov S, Milicic D, Bergovec M, Planinc D. Treatment and secondary prevention of ischemic coronary events in croatia (taspic-cro study). Eur J Cardiovasc Prev Rehabil. 2006;13(4):646-54.

Vrazic H, Sikic J, Lucijanic T, et al. The prevalence of overweight and obesity among croatian hospitalized coronary heart disease patients. Coll Antropol. 2012;36 (Suppl 1):211-6.




DOI: http://dx.doi.org/10.24125/sanamed.v11i2.105

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 SANAMED

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.